Nuclein, LLC Company Profile

Background

Nuclein, LLC, established in 2017 and headquartered in Austin, Texas, is a biotechnology company dedicated to providing simple, affordable, rapid, and accurate diagnostic testing solutions. The company's flagship product, the DASH® Rapid PCR System, delivers lab-quality, point-of-care PCR results in 15 minutes, enabling swift and reliable detection of infectious diseases. Nuclein's mission is to revolutionize diagnostic testing by making it accessible and efficient for healthcare providers and patients alike.

Key Strategic Focus

Nuclein's strategic focus centers on the development and commercialization of innovative diagnostic platforms that facilitate rapid and accurate disease detection at the point of care. The company specializes in molecular diagnostics, particularly polymerase chain reaction (PCR) testing, and aims to expand its test menu to include various infectious diseases, sexually transmitted infections (STIs), and other conditions. By leveraging its proprietary technology, Nuclein seeks to enhance patient care through timely and precise diagnostics.

Financials and Funding

As of December 2025, Nuclein has raised approximately $50 million in funding. In March 2021, the company closed a $14 million Series B funding round led by Trinity Private Equity Group, a Southlake, Texas-based private equity firm. This investment supports Nuclein's efforts to commercialize its novel, hand-held PCR platform designed as a disposable, all-in-one, self-test for infectious disease diagnosis. In August 2024, Nuclein raised an additional $8.79 million in an amended filing from an offering of $15 million. The funds are intended to advance the development and distribution of Nuclein's diagnostic products.

Pipeline Development

Nuclein's primary pipeline candidate is the DASH® Rapid PCR System, which has received FDA 510(k) clearance and a CLIA waiver for its DASH® SARS-CoV-2 & Flu A/B Test. This system delivers lab-quality PCR results in 15 minutes, enabling rapid detection of COVID-19 and influenza A/B viruses. The company plans to expand its test menu to include other upper respiratory infections, STIs, and various other conditions, aiming to provide comprehensive diagnostic solutions at the point of care.

Technological Platform and Innovation

Nuclein's proprietary technological platform is the DASH® Rapid PCR System, a compact benchtop solution that delivers lab-quality PCR results in just 15 minutes. The system is designed for ease of use, requiring less than one minute of hands-on time, and supports multiplex testing across various sample types. It features Wi-Fi and cloud connectivity for data management and is built to be multiplex-capable in a single cartridge. This innovation enables rapid and accurate diagnostics at the point of care, enhancing patient outcomes through timely decision-making.

Leadership Team

Nuclein's leadership team comprises experienced professionals with diverse backgrounds in biotechnology and diagnostics:

Alan Blake: Chief Executive Officer and Co-Founder. Prior to Nuclein, Mr. Blake co-founded Yorktown Technologies LP, known for developing GloFish®, the first widely commercialized biotech animal. He holds a Bachelor of Business Administration in finance from the University of Texas at Austin and has 25 patents to his name.

Dr. Richard Crockett: President and Co-Founder. Dr. Crockett co-founded Yorktown Technologies and has extensive experience in research, development, production, and regulatory affairs within the biotechnology sector.

Jeffrey Stukuls: Chief Financial Officer. Mr. Stukuls has a background in technology development, online retail, and services industries, with expertise in raising substantial funding and scaling businesses. He graduated from Bentley University with a Bachelor of Science in Accountancy and a minor in Computer Information Systems.

Reid Sadler: Chief Commercial Officer. Mr. Sadler brings over 30 years of sales and marketing experience in the in-vitro diagnostics and biotechnology industries, having held leadership roles at Roche Diagnostics, Immucor, Luminex, and Binx Health.

Dr. Joern Mosner: Chief Scientific Officer. Dr. Mosner has over 25 years of experience in the In Vitro Diagnostics industry, with a focus on molecular diagnostics and assay development. He has held positions at Siemens Medical Solutions and Luminex.

Huiping Zhu, PhD: Vice President of Assay Development. Dr. Zhu has led molecular diagnostic product development and design verification, with over 60 peer-reviewed scientific publications in molecular diagnostics, human genetics, and developmental biology.

Steve Truffer: Vice President of Sales. Mr. Truffer has over 35 years of experience in sales and marketing within the in-vitro diagnostics, medical device, and life sciences sectors, having held leadership roles at Roche Diagnostics, LGC Clinical Diagnostics, and Beckman Coulter.

Mark Hunter: Vice President of Operations. Mr. Hunter brings over 25 years of leadership experience in the medical device, diagnostics, and life sciences industries, with previous roles at Luminex Corporation, Abbott Laboratories, and Intel Corporation.

Geoff Richman: Senior Director of Marketing. Mr. Richman has over 15 years of marketing experience in the in-vitro diagnostics and medical device industries, with positions at Binx Health, Pillar Biosciences, Boston Scientific, and Novartis.

Miranda Chavez: Director of Program & Project Management. Ms. Chavez oversees program and project management at Nuclein, contributing to the company's operational efficiency and project execution.

Martin Kochanczyk, PhD: Director of Systems Integration. Dr. Kochanczyk focuses on developing sample-to-answer diagnostic systems, with experience leading diverse R&D teams at Luminex Corporation and Pattern Bioscience.

Michael Karberg, PhD: Chief Scientist. Dr. Karberg has extensive experience in nucleic acid assay development and optimization, having developed over 100 assays in previous roles at Life Technologies and Thermo Fisher Scientific.

Leadership Changes

In 2023, Nuclein merged with Minute Molecular Diagnostics, Inc., a Northwestern University spin-out that initially developed the DASH® Rapid PCR System. This strategic move aimed to enhance Nuclein's technological capabilities and expand its product offerings in the diagnostic testing market.

Competitor Profile

Market Insights and Dynamics

The molecular diagnostics market, particularly point-of-care PCR testing, is experiencing significant growth due to the increasing demand for rapid and accurate disease detection. Advancements in technology and the need for efficient healthcare solutions are driving the adoption of point-of-care diagnostics, presenting opportunities for companies like Nuclein to expand their market presence.

Competitor Analysis

Nuclein operates in a competitive landscape with several key players:

Biomeme: A Philadelphia-based company specializing in portable PCR devices and cell-based assay systems.

Visby Medical: A San Jose, California-based company developing single-use PCR diagnostic devices for infectious diseases.

ACON Laboratories: A global company offering a range of diagnostic products, including point-of-care testing solutions.

These competitors are actively developing and commercializing diagnostic platforms, contributing to the dynamic and evolving market landscape.

Strategic Collaborations and Partnerships

In October 2025, Nuclein announced a strategic partnership with BTNX Inc., a global leader in rapid diagnostic testing. This collaboration includes a lead investment in Nuclein's recent financing round and a global distribution agreement for their DASH® Rapid PCR System. The partnership aims to expand and strengthen the product portfolios of both companies, positioning them at the forefront of the rapidly growing molecular point-of-care market.

Operational Insights

Nuclein's strategic considerations include differentiating its products through rapid, accurate, and user-friendly diagnostic solutions. The company's focus on point-of-care testing and its commitment to innovation provide a competitive edge in the market. By leveraging its technological platform and strategic partnerships, Nuclein aims to enhance its market position and drive growth in the diagnostic testing sector.

Strategic Opportunities and Future Directions

Nuclein's strategic roadmap involves expanding its product offerings to include a broader range of infectious diseases and other health conditions. The company plans to leverage its proprietary technology and partnerships to provide comprehensive, rapid diagnostic solutions that meet the growing demand in healthcare settings.